Mission to BioKorea to strengthen ties

AusBiotech is pleased to support Austrade’s BioKorea 2022 delegation to strengthen reciprocal relationships and showcase Australia’s investment opportunities and life sciences capabilities.

AusBiotech CEO Lorraine Chiroiu will deliver an opening keynote ‘Australian biopharma industry and investment trends’ during the Australia-Korea Innovation Seminar at BioKorea on 11 May, promoting opportunities in Australia, and joining Julie Quinn, Senior Trade and Investment Commissioner, Austrade Seoul will speak on ‘investment opportunities in Australia’.

AusBiotech’s support of BioKorea 2022, which will be in-person from 11-13 May, is part of its global strategy, as it facilitates international opportunities for investment discussions, collaborations and partnerships, with a focus on the markets important to members.

AusBiotech is continuing to facilitate these ongoing investment opportunities, which is crucial for the growth of the Australian life sciences sector, and ultimately for continuing Australia’s position in the sector globally.

The organiser of BioKorea, Korea Health Industry Development Institute (KHIDI), has led large Korean delegations to AusBiotech for several years, demonstrating the strong interest Korean companies have in collaborating with Australia’s biotech industry. KHIDI is a government agency affiliated to the Ministry of Health and Welfare that also supports KoBIA. AusBiotech is looking forward to welcoming another large Korean delegation to AusBiotech 2022 in Perth later this year. AusBiotech’s long-standing MoU with KHIDI will continue to make a solid platform for further international collaborations.

The Austrade Australian delegation provides plenty of opportunities for Australian companies to meet potential new partners, make international connections and explore investment opportunities.

On the trip, AusBiotech intends to sign a memorandum of understanding (MoU) with KoBIA (Korea Biomedicine Industry Association) at BioKorea 2022 to strengthen and generate collaboration opportunities between Australian and Korean biotech and pharmaceutical businesses. KoBIA is an industry association under the Ministry of Health and Welfare that represents over 140 bio and pharmaceutical companies, including vaccine developers. Its mission and roles can be found here.

AusBiotech also has an MoU with the Council for Advanced RM (CARM), Korea’s regenerative medicine industry association.

/Public Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.